On July 11, 2017, Alan B. Colowick, Ph.D., submitted his resignation as an independent director of the Board of Directors of Achaogen, Inc. and as a member of the Audit Committee and the Compensation Committee of the Board, effective at the close of business on July 31, 2017. Dr. Colowick is planning to focus on his new role as a partner at Sofinnova Ventures. On July 11, 2017, the Board appointed Karen Bernstein, Ph.D., effective immediately, to serve as a member of the Board. Dr. Bernstein was appointed as a Class I director, with an initial term expiring at the company's 2018 annual meeting of stockholders, filling a vacancy. Dr. Bernstein was also elected to serve as a member of the Nominating and Corporate Governance Committee of the Board. The Board has determined that Dr. Bernstein is independent as defined in Listing Rule 5605 of The NASDAQ Stock Market LLC for purposes of serving on the Nominating Committee.